Validation of a Novel Three-Dimensional (
angiogenesis
clear cell renal cell carcinoma
immunity
immunohistochemistry
intratumoral heterogeneity
tumor sampling
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
30 Apr 2022
30 Apr 2022
Historique:
received:
24
03
2022
revised:
23
04
2022
accepted:
26
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
We aimed to overcome intratumoral heterogeneity in clear cell renal cell carcinoma (clearRCC). One hundred cases of clearRCC were sampled. First, usual standard sampling was applied (1 block/cm of tumor); second, the whole tumor was sampled, and 0.6 mm cores were taken from each block to construct a tissue microarray; third, the residual tissue, mapped by taking pieces 0.5 × 0.5 cm, reconstructed the entire tumor mass. Precisely, six randomly derived pieces of tissues were placed in each cassette, with the number of cassettes being based on the diameter of the tumor (called multisite 3D fusion). Angiogenic and immune markers were tested. Routine 5231 tissue blocks were obtained. Multisite 3D fusion sections showed pattern A, homogeneous high vascular density (10%), pattern B, homogeneous low vascular density (8%) and pattern C, heterogeneous angiogenic signatures (82%). PD-L1 expression was seen as diffuse (7%), low (33%) and absent (60%). Tumor-infiltrating CD8 scored high in 25% (pattern hot), low in 65% (pattern weak) and zero in 10% of cases (pattern desert). Grading was upgraded in 26% of cases (G3-G4), necrosis and sarcomatoid/rhabdoid characters were observed in, respectively, 11 and 7% of cases after 3D fusion (
Identifiants
pubmed: 35629151
pii: jpm12050727
doi: 10.3390/jpm12050727
pmc: PMC9147893
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Urology. 1998 May;51(5):693-6
pubmed: 9610581
Cancer. 2020 Sep 15;126(18):4156-4167
pubmed: 32673417
Dev Cell. 2018 Jun 18;45(6):681-695.e4
pubmed: 29920274
Pathol Oncol Res. 2002;8(2):129-32
pubmed: 12172577
EMBO Rep. 2012 Jun 01;13(6):528-38
pubmed: 22595889
Nat Genet. 2014 Mar;46(3):225-233
pubmed: 24487277
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
Clin Cancer Res. 2001 Mar;7(3):533-7
pubmed: 11297244
N Engl J Med. 2012 Mar 8;366(10):956-7
pubmed: 22397658
Hum Pathol. 2001 Nov;32(11):1209-15
pubmed: 11727260
Clin Cancer Res. 2007 Jan 1;13(1):161-9
pubmed: 17200351
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
N Engl J Med. 2019 Mar 21;380(12):1176-1178
pubmed: 30779526
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Br J Urol. 1997 Sep;80(3):401-4
pubmed: 9313657
Am J Surg Pathol. 2009 Jul;33(7):1031-6
pubmed: 19384190
Diagn Pathol. 2014;9 Suppl 1:S12
pubmed: 25565219
BJU Int. 2010 May;105(9):1247-54
pubmed: 19863525
Ann Oncol. 2020 Aug;31(8):1030-1039
pubmed: 32339648
N Engl J Med. 2018 Apr 5;378(14):1344-1345
pubmed: 29562143
J Clin Pathol. 2012 Feb;65(2):106-13
pubmed: 21965832
Cancer Cell. 2020 Dec 14;38(6):803-817.e4
pubmed: 33157048
Cancer Cell. 2020 May 11;37(5):720-734.e13
pubmed: 32359397
Hum Pathol. 2007 Oct;38(10):1454-62
pubmed: 17889675
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Urology. 1995 Jul;46(1):27-30
pubmed: 7604476
J Cancer Res Clin Oncol. 1998;124(3-4):141-7
pubmed: 9619739
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
APMIS. 2016 Mar;124(3):153-9
pubmed: 26865355
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Am J Surg Pathol. 2013 Oct;37(10):1505-17
pubmed: 24025521
F1000Res. 2016 Mar 22;5:385
pubmed: 27127618
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Histopathology. 2019 Jan;74(1):4-17
pubmed: 30565310
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
Mod Pathol. 2021 Jun;34(6):1167-1184
pubmed: 33526874